Find Irofulven manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Hmaf, Mgi 114, 158440-71-2, 6-hydroxymethylacylfulvene, (-)-irofulven, Mgi-114
Molecular Formula
C15H18O3
Molecular Weight
246.30  g/mol
InChI Key
NICJCIQSJJKZAH-AWEZNQCLSA-N
FDA UNII
6B799IH05A

Irofulven
A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted fast track status by the U.S. Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers. MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.
1 2D Structure

Irofulven

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(5'R)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one
2.1.2 InChI
InChI=1S/C15H18O3/c1-8-6-10-12(11(8)7-16)9(2)15(4-5-15)14(3,18)13(10)17/h6,16,18H,4-5,7H2,1-3H3/t14-/m0/s1
2.1.3 InChI Key
NICJCIQSJJKZAH-AWEZNQCLSA-N
2.1.4 Canonical SMILES
CC1=C(C2=C(C3(CC3)C(C(=O)C2=C1)(C)O)C)CO
2.1.5 Isomeric SMILES
CC1=C(C2=C(C3(CC3)[C@@](C(=O)C2=C1)(C)O)C)CO
2.2 Other Identifiers
2.2.1 UNII
6B799IH05A
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 6-(hydroxymethyl)acylfulvene

2. 6-hydroxymethylacylfulvene

3. Hmaf Cpd

4. Mgi 114

5. Mgi-114

6. Mgi.114

2.3.2 Depositor-Supplied Synonyms

1. Hmaf

2. Mgi 114

3. 158440-71-2

4. 6-hydroxymethylacylfulvene

5. (-)-irofulven

6. Mgi-114

7. Nsc 683863

8. (hydroxymethyl)acylfulvene

9. Nsc-683863

10. (5'r)-5'-hydroxy-1'-(hydroxymethyl)-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one

11. 6b799ih05a

12. Lp-100

13. (r)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro(cyclopropane-1,5'-(5h)inden)-7'(6'h)-one

14. 6-(hydroxymethyl)acylfulvene

15. Acylfulvene, 6-(hydroxymethyl)-

16. Irofulven [usan:inn]

17. Unii-6b799ih05a

18. Mgi.114

19. Irofulven [inn]

20. Irofulven [mi]

21. Irofulven (usan/inn)

22. Irofulven [usan]

23. Irofulven [who-dd]

24. Schembl8800

25. Chembl118218

26. Dtxsid50166423

27. Chebi:135002

28. Zinc3916310

29. Bdbm50410835

30. Nsc683863

31. Akos027256650

32. Db05786

33. (r)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-inden]-7'(6'h)-one

34. Hy-14429

35. Nci60_030149

36. Spiro(cyclopropane-1,5'(5h)-inden)-7'(6'h)-one, 6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethyl-, (r)-

37. Cs-0003353

38. D04614

39. Q6072197

2.4 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 246.30 g/mol
Molecular Formula C15H18O3
XLogP3-0.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count3
Rotatable Bond Count1
Exact Mass246.125594432 g/mol
Monoisotopic Mass246.125594432 g/mol
Topological Polar Surface Area57.5 Ų
Heavy Atom Count18
Formal Charge0
Complexity558
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in brain cancer, breast cancer, endometrial cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, pediatric indications, prostate cancer, and sarcoma.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Antineoplastic Agents, Alkylating

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)


Radiation-Sensitizing Agents

Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. (See all compounds classified as Radiation-Sensitizing Agents.)


5.2 Mechanism of Action

MGI-114(Irofulven) has unique mechanism of action as an anti-tumor agent is due to its ability to be rapidly absorbed by tumor cells. Once inside the cells, the compound binds to DNA and protein targets. This binding interferes with DNA replication and cell division of tumor cells, leading to tumor-specific apoptotic cell death, or cell suicide. During this process, tumor cells tend to automatically shut themselves down when they sense their function is compromised.


ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty